Background: Bone metastases are common in patients with advanced non-small-cell lung cancer (NSCLC) and can have devastating consequences. Preventing or delaying bone metastases may improve outcomes. 
calcium supplementation and were randomized to i.v. ZOL (every 3-4 weeks) or no treatment (control). The primary end point was progression-free survival (PFS).
Results: No significant intergroup differences were observed in PFS or overall survival (OS). Median PFS was 9.0 months with ZOL versus 11.3 months for control. Fifteen ZOL-treated (6.6%) and 19 control patients (9.0%) developed bone metastases. Estimated 1-year OS was 81.8% for each group. ZOL safety profile was consistent with previous clinical data, but with higher discontinuations versus control. Fifteen ZOL-treated (6.6%) and five control patients (2.3%) had renal adverse events. Two cases of osteonecrosis of the jaw were reported.
Conclusions: ZOL did not significantly affect PFS or OS in stage IIIA/B NSCLC patients with controlled disease, with a trend toward worsening PFS in the longer-term follow-up. Few patients experienced bone metastases, possibly limiting the potential ZOL impact on disease course. Key words: adjuvant treatment, non-small-cell lung cancer, survival, zoledronic acid introduction Lung cancer remains the most common cancer in the world in terms of cases (1.6 million annually) and deaths (1.4 million annually) [1] . For patients with stage IV non-small-cell lung cancer (NSCLC), the incidences of bone metastases at diagnosis and at follow-up are relatively high (30%-40%), and once a patient develops metastases, such as bone lesions, the 5-year survival rate is <5% and median overall survival (OS) is <6 months [2] . Therefore, preventing metastases to bone may be a valid treatment approach to improve survival outcomes in patients with advanced, non-metastatic disease.
The standard treatment for patients with stage IIIA/B disease varies based on tumor size and anatomic location. First-line treatment is often multimodal and may include different combinations of surgery (if indicated) and/or chemotherapy and/or radiation [3] . Bisphosphonate (BP) treatment is generally recommended in patients with symptomatic bone metastases, but not for patients with stage IIIA/B disease [4] . However, emerging preclinical and clinical evidence suggests that BPs may provide anticancer benefits in various solid tumors and in patients with multiple myeloma [5] . A number of studies also suggest that zoledronic acid (ZOL) may provide clinically meaningful anticancer benefits in patients with advanced NSCLC [6] [7] [8] . However, survival benefits in NSCLC patients treated with ZOL were reported only in patients with bone metastases, and the anticancer benefits were most apparent in the subsets of patients with especially high rates of bone destruction. Interestingly, in a small, open-label, randomized pilot study in 40 patients with recurrent or metastatic solid tumors but without bone metastases, treatment with ZOL significantly increased bone-metastasis-free survival at 12 months (60% versus 10%; P < 0.0005) and 18 months (20% versus 5%; P = 0.0002) versus no treatment, suggesting that, in addition to delaying disease progression within the bone, ZOL may also prevent the formation of bone metastases [9] . However, this was a small study, and further investigation is necessary to determine whether ZOL can indeed prevent or delay bone metastases or have meaningful anticancer benefits in patients with nonmetastatic NSCLC (i.e. stage IIIA/B).
Accordingly, this open-label G2419 study (NCT00172042) evaluated whether the addition of ZOL 4 mg every 3-4 weeks for up to 2 years in patients with stage IIIA/B NSCLC with response and non-progressive disease after first-line therapy could improve progression-free survival (PFS), delay time to bone metastases and disease progression, and/or reduce the risk of skeletal-related events (SREs), the rate of bone metastases, and mortality.
methods patient population
Eligible patients were ≥18 years of age, with histologically or cytologically confirmed stage IIIA or IIIB NSCLC at diagnosis. All patients had to have received and responded to primary treatment for their disease (i.e. objective response, stable disease, or non-evaluable disease) with no progression of their NSCLC within the 8-month period before randomization. Additional eligibility criteria included Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; adequate renal, hematologic, and hepatic function; and life expectancy of ≥6 months. Patients with pleural effusion at baseline, thoracotomy ≤3 weeks before enrollment, metastases, prior BPs in the past 12 months, current active dental problems including the infection of the teeth or jawbone (maxillar or mandibular), dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ) were excluded. All patients provided written informed consent before the initiation of any study procedure, and the study was approved by the appropriate ethics committees.
The intent-to-treat (ITT) population included all randomized patients and was assessed according to the treatment assigned at randomization.
study design and treatment
Eligible patients were randomized 1:1 to ZOL or no treatment (control group) (Figure 1 ) [10] . Patients in the treatment group received ZOL as a 15-min infusion every 3-4 weeks for 24 months. The starting dose of ZOL was adjusted for renal function as recommended in the prescribing information [10] . At development of bone metastases, patients in the control group were to receive ZOL and continue the treatment until 24 months from study entry. All patients received oral supplementation with calcium 500 mg and vitamin D 400-500 IU daily throughout the course of the study.
study end points
The primary end point of the study was PFS. Secondary end points included time to occurrence of bone metastases; rate of bone metastases (symptomatic or asymptomatic) at 6, 12, 18, and 24 months; time to disease progression; time to first SRE; and OS at 12 and 24 months. SREs were defined as spinal cord compression, pathologic bone fractures, and the need for radiation therapy (including the use of radioisotopes) or surgery to bone.
study assessments
Bone scans were carried out every 6 months (at screening, and at months 6, 12, 18, and 24) or when symptoms of bone metastases were reported. In the case of a positive bone scan, sites showing high uptake of radioactive substance were further evaluated using other diagnostic methods [e.g. X-rays, magnetic resonance imaging (MRI), or computed tomography (CT) scan] to confirm the presence of bone metastases. Patients without metastasis to the bone at the end of their last evaluation were censored for the bone metastasis end point thereafter.
Disease progression was assessed by CT, MRI, or X-ray of the chest, with evaluations every 3 months. Other instrumental evaluations were carried out to detect distant metastases, if clinically indicated. The imaging method used for the evaluation of primary disease during the course of the study was required to be the same as that used in the initial screening. In patients with non-resected or incompletely resected primary tumors, tumor response was assessed per RECIST guidelines [11] .
Safety was assessed by continuous adverse event (AE) monitoring. At each visit, serum biochemistry, complete blood counts, and urinalysis were carried out, and vital signs, physical condition, and body weight were evaluated. The safety population included all patients who had at least one post-baseline safety assessment, and was analyzed according to the treatment received before bone metastases. The National Cancer Institute Common Toxicity Criteria were used for grading the severity of AEs [12] .
An AE was designated as a possible case of ONJ if the following criteria were met: exposed bone in the maxillofacial area that occurred either spontaneously or after dental surgery with no evidence of healing for more than 3-6 weeks after appropriate care, in the absence of prior radiation to the head or neck. Once a diagnosis of ONJ was made, it was reported and followed as a serious AE (SAE) regardless of the severity of the ONJ case, without adjudication.
statistical methods and considerations
Unless otherwise specified, all statistical tests were two-sided and used a significance level of 0.05. The primary efficacy end point was PFS, defined as the time from randomization to the date of first documented progression, recurrence, or death from any cause. A log-rank test was used to compare the treatment groups. Time-to-event end points were estimated using the Kaplan-Meier method [13] . Efficacy analyses were carried out using the ITT population.
The median PFS for stage IIIA/B NSCLC patients was predicted to be 13 months for the control group based on previous trials that reported median PFS of 15-18 months and 11-13 months for stage IIIA and IIIB NSCLC patients, respectively [14] . Based on a one-sided log-rank test at a significance level of 0.025, 247 events would be needed to generate 80% power to detect a hazard ratio of 0.7, which corresponds to an increase in the median PFS or disease-free survival from 13 months in the control group to 18.6 months in the ZOL group. Assuming a dropout rate of 30%, the target enrollment for this study was estimated to be approximately 433 patients.
results patients A total of 437 patients were randomized to either ZOL or no treatment (control; supplementary Figure S1 , available at Annals of Oncology online). Most patients were Caucasian (77.1%), and there were similar proportions of patients with stage IIIA or IIIB cancer in each group (Table 1) . Nodal status at diagnosis was not captured in the clinical database. Overall, 154 patients (35.2%) completed the study [68 patients (30.1%) in the ZOL group and 86 patients (40.8%) in the control group] and 64.8% discontinued the study treatment [158 patients (69.9%) in the ZOL arm and 125 patients (59.2%) in the control arm]. The most frequent reasons for discontinuation were death (18.6% and 19.9% in the ZOL and control groups, respectively), consent withdrawal (16.4% and 11.8% in the ZOL and control groups, respectively), and AEs (11.9% and 6.2% in the ZOL and control groups, respectively). Overall, 20 patients in the control arm received ZOL: 19 for bone metastases and 1 without bone metastases who received ZOL in error ( protocol violation). The median time to starting ZOL among these 20 patients in the control group was 7.9 months.
efficacy
There was no significant difference in PFS for ZOL versus control (P = 0.096), with 155 events (68.6%) in the ZOL group compared with 129 events (61.1%) in the control group. The dose of ZOL was adjusted based on renal function, as described in the prescribing information [10] . CR, complete response; i.v., intravenous; NED, non-evaluable disease; NSCLC, non-small-cell lung cancer; PD, progressive disease; PR, partial response; SD, standard deviation; ZOL, zoledronic acid.
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Median PFS was 9.0 months (95% CI = 6.8-12.4 months) for the ZOL group and 11.3 months (95% CI = 7.7-15.8 months) for the control group ( Table 2 ). The estimated Kaplan-Meier PFS rates at 24 months were 25.7% (95% CI = 19.8% to 32.0%) for the ZOL group and 36.0% (95% CI = 29.2% to 42.8%) for the control group (hazard ratio = 1.22; 95% CI = 0.96-1.54; logrank P = 0.0957). Overall in the ITT population, only 34 confirmed bone metastasis events occurred (15 in the ZOL group, 19 in the control group) ( Table 3) .
There were 88 (38.9%) and 75 (35.5%) deaths observed in the ZOL and control groups, respectively. Median survival was 30.3 months for ZOL and was not reached for the control group (Table 2) ; however, the risk of death was similar between the treatment groups (hazard ratio = 1.17; 95% CI = 0.86-1.59; log-rank P = 0.3216). The estimated Kaplan-Meier OS rates at 12 and 24 months for the ZOL group were 81.8% and 59.5%, respectively. The survival rates at 12 and 24 months for the control group were 81.8% and 63.6%, respectively. Few SREs were reported, affecting five patients (2.2%) in the ZOL group and three patients (1.4%) in the control group.
exposure and safety
The median number of infusions administered was 15 for the ZOL group and 6 for the control group (n = 20) that received ZOL. The median duration of exposure to ZOL was 14.5 months (range 0-26.5 months) for patients in the ZOL group and 4.0 months (range 0-21.0 months) for the control group. A total of 202 patients (90.2%) in the ZOL group and 176 patients (82.6%) in the control group experienced treatmentemergent AEs (supplementary Table S1 , available at Annals of Oncology online). Of the most commonly reported AEs (≥10%), pyrexia, fatigue, and constipation occurred in at least 4% more patients in the ZOL group compared with control. Overall, 15 patients (6.7%) in the ZOL group had renal function AEs compared with 5 patients (2.3%) in the control group. Only two cases of ONJ were reported in this study, one each from the control and ZOL arms, respectively. Both were grade 2 and are ongoing. The patient in the ZOL arm, a 62- discussion ZOL has proven clinical benefit for maintaining skeletal health and reducing the risk of SREs in patients with malignant bone disease. More recently, data suggestive of anticancer benefits from ZOL in multiple tumor types have emerged [5] . For example, retrospective analyses of phase III trial data show that ZOL improved survival in patients with bone metastases from NSCLC who had high bone turnover rates at study entry [15] . Furthermore, ZOL prolonged survival versus no ZOL in a pilot study in NSCLC patients with bone metastases and stage IV disease (N = 144) [7] . Notably, the patients in both these studies had skeletal involvement at study entry. These data are consistent with preclinical and translational studies, suggesting that, in addition to the established SRE-prevention benefits, ZOL may provide anticancer benefits through direct effects on tumor cells and/or by modifying the bone microenvironment to suppress tumor growth, inhibit tumor-mediated angiogenesis, and enhance host antitumor response [5] . Because ZOL is inherently bone-directed and potentially capable of inhibiting tumor progression at multiple steps, it was hypothesized that ZOL might improve survival in patients with stage IIIA/B NSCLC whose disease was under control and who had no metastasis at study entry, ostensibly by inhibiting bone metastases or progression to other sites. The key assumptions underlying this hypothesis are that the bone marrow may play a critical role in disease progression, recurrence, and/or survival by harboring disseminated tumor cells (DTCs), and that metastasis to the bone is a critical determinant of survival outcome. Indeed, the former assumption appears valid in the case of patients with earlystage breast cancer, in whom the presence of DTCs in the bone marrow correlates with cancer-related outcome [16, 17] and ZOL treatment reduces and/or eliminates DTCs [18] . However, whereas SREs may correlate with reduced survival, bone metastases themselves do not correlate with poor survival prognosis compared with visceral metastases in patients with NSCLC [19] . In the current study, no bone marrow aspirations were obtained and the role of DTCs was not evaluated. Furthermore, biochemical markers of bone metabolism were not monitored. However, more than half of the participating patients experienced disease progression events (60%), and only a small proportion of these included bone metastases (7.8%). Thus, in the trial population, sites of recurrent disease were largely outside of bone, and targeting the bone microenvironment with ZOL had no apparent effects on the disease course. Indeed, because the primary site of the disease is the lung, it is possible that the systemic spread of the disease is aided by direct access of tumor cells to the host vasculature or that cancer cells may spread through the thoracic cavity or lymphatic systems. Therefore, DTCs in the bone marrow microenvironment may be largely irrelevant to improving cancer-related outcome in the enrolled study population, wherein the high incidence of recurrence outside of bone may be the major determinant of PFS and OS. Thus, one is left to conclude that the efficacy of BPs in patients with advanced NSCLC may be restricted to patients with skeletal involvement. These data are consistent with data from a recent study by Pandya et al. [20] , in which adding ZOL to standard chemotherapy did not improve cancer-related outcomes compared with chemotherapy alone in patients with inoperable stage IIIB or stage IV NSCLC who had no bone involvement, although it may be argued that the number of patients in this study was small and the duration of ZOL treatment was short. Similarly, although ZOL has been shown to inhibit tumor progression by inhibiting angiogenesis [21] or stimulating host antitumor immune response [22, 23] , the therapeutic relevance of these activities in the NSCLC disease course is not known.
The current trial presents important prospective data on the incidence of disease progression and bone metastases in patients with controlled stage III NSCLC after the completion of primary treatment. In this study, patients treated with ZOL had a numerically lower incidence and slight delay in the onset of bone metastases. However, the data were not statistically significant, nor did this translate into an observable benefit in the overall disease outcome. In both PFS and OS analyses, the later time points showed a trend toward a worsening outcome in the ZOL group compared with the control group. In addition, the number of patients discontinuing treatment because of AEs was higher in the ZOL group. However, in this study, disease predominantly progressed in sites other than bone, limiting potential anticancer benefits of ZOL. Thus, the clinical efficacy of ZOL in the NSCLC setting may be more pronounced in patients with skeletal involvement. Indeed, it should be noted that, with the baseline screening for bone metastases, it is likely that many patients with early and asymptomatic bone lesions who would not have been diagnosed using standard screening practices (which recommend bone scans only in the event of symptoms of bone metastases) were excluded from this study [24] . In patients with early bone disease, ZOL could still have the potential to deter progression to overt bone metastases. Further studies in patients without malignant involvement in the bone at baseline are not warranted until patients at high risk for bone metastases can be identified. 
